PA2G4 Antibody

What is PA2G4 and why is it important in cancer research?

PA2G4 (EBP1), first identified as an ErbB3 binding protein, is a 38 kDa protein widely expressed in cultured cells and tissues . This protein contains several functional domains including a nuclear localization sequence (NLS), LxxLL and LxCxE motifs, indicating its involvement in cell signaling pathways and gene transcription regulation .

The significance of PA2G4 in cancer research stems from its context-dependent role as either an oncogene or tumor suppressor. PA2G4 is upregulated in multiple cancers including nasopharyngeal carcinoma, hepatocellular carcinoma, cervical cancer, and salivary adenoid cystic carcinoma . Conversely, it's downregulated in HER2+ breast cancer, bladder cancer, and prostate cancer . This differential expression pattern makes PA2G4 an important subject for cancer biology investigations and a potential therapeutic target.

What isoforms of PA2G4 exist and how are they detected?

PA2G4 exists in at least two isoforms:

• PA2G4-p48: The predominant isoform in many cancer tissues, observed at approximately 48 kDa

• PA2G4-p42: A less abundant isoform, observed at approximately 38-42 kDa

When conducting Western blot analysis, researchers should be aware that while the calculated molecular weight of PA2G4 is 44 kDa, observed molecular weights typically range from 38-42 kDa and 48 kDa depending on the isoform . In hepatocellular carcinoma studies, PA2G4-p48 was identified as the main expressed isoform, with PA2G4-p42 almost undetectable .

What applications are PA2G4 antibodies validated for?

PA2G4 antibodies have been validated for multiple research applications:

What are optimal protocols for PA2G4 antibody use in immunohistochemistry?

For successful immunohistochemical detection of PA2G4:

Antigen Retrieval:

• Primary recommendation: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

Antibody Dilution Ranges:

• For polyclonal antibodies (e.g., 15348-1-AP): 1:50-1:500

• For monoclonal antibodies (e.g., 66055-1-Ig): 1:50-1:500

Expected Localization:
PA2G4 protein expression is typically observed in the cytoplasm of malignant tumor cells and full thickness nasopharyngeal mucosa epithelium, including cilia . Proper identification of this subcellular localization is critical for accurate interpretation of staining patterns.

Positive Controls:
Human breast cancer tissue has been validated as a reliable positive control for PA2G4 immunohistochemistry .

How should PA2G4 antibody specificity be validated?

A comprehensive validation strategy includes:

• Multiple antibody comparison: Use antibodies targeting different epitopes of PA2G4, such as:

  • Antibodies targeting AA 1-394

  • Antibodies targeting AA 322-350 (C-term)

  • Antibodies targeting AA 228-255

  • Antibodies targeting AA 1-110

• Genetic validation: Compare staining between:

  • Wild-type samples

  • PA2G4 knockdown or knockout samples (several publications have utilized this approach)

• Molecular weight verification: Confirm band patterns in Western blot match expected molecular weights:

  • 38-42 kDa (PA2G4-p42 isoform)

  • 48 kDa (PA2G4-p48 isoform)

• Cross-reactivity assessment: Verify antibody performance across species when conducting comparative studies. Available antibodies show reactivity with human, mouse, rat, and in some cases dog, cow, and zebrafish samples .

What are the optimal conditions for PA2G4 immunoprecipitation experiments?

For successful immunoprecipitation of PA2G4:

Antibody-to-lysate ratio:

• Recommended range: 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate

Validated cell types:

• Jurkat cells have been confirmed as positive for PA2G4 immunoprecipitation

Buffer considerations:
For studying PA2G4-protein interactions, consider using:

• Surface plasmon resonance (SPR) experiments in HEPES Buffered Saline (HBS) (20 mM phosphate (pH 7.5) 137 mM NaCl, 2.7 mM KCl, and 0.05% Tween 20)

• For recombinant PA2G4 studies, PBS buffer exchange via overnight dialysis at 4°C has been successful

How does PA2G4 expression correlate with clinical outcomes in different cancer types?

PA2G4 expression shows distinct correlations with clinical outcomes across cancer types:

Nasopharyngeal Carcinoma (NPC):

Hepatocellular Carcinoma (HCC):

These findings highlight the potential of PA2G4 as a prognostic biomarker, particularly in advanced cancer stages.

What are the molecular mechanisms by which PA2G4 influences cancer progression?

PA2G4 influences cancer progression through multiple pathways:

In Hepatocellular Carcinoma:

• PA2G4 binds to YTHDF2, stabilizing FYN mRNA

• This interaction increases HCC cell mobility in vitro and promotes lung metastasis in vivo

• PA2G4 also promotes cell proliferation via Ebp1/p38/HIF1α signaling and MDM2-mediated downregulation of p53

In Acute Myeloid Leukemia (AML):

• PA2G4 functions at the crosstalk of the EVI1 leukemogenic signal

• PA2G4 overexpression rescues AML cells from histone deacetylase inhibitors (HDACis)

• Genetic and pharmacological inhibition of PA2G4 abrogates EVI1 in 3q26 AML cells, including in patient-derived leukemia xenografts

These mechanistic insights explain PA2G4's context-dependent roles across different cancer types and highlight its potential as a therapeutic target.

What approaches are being developed to target PA2G4 in cancer therapy?

Several promising therapeutic approaches targeting PA2G4 are under development:

• Direct inhibition of PA2G4 protein-protein interactions:

  • Compound WS6 has been developed to disrupt the oncogenic PA2G4-MYCN protein-protein interface

  • Computational approaches including Fast-Rigid Exhaustive Docking (FRED) have been used to optimize binding of these inhibitors to PA2G4

• HDACi-based combination therapies:

  • In 3q26 acute myeloid leukemia, histone deacetylase inhibitors (HDACis) emerge as potent repressors of the PA2G4-EVI1 axis

  • These findings suggest HDACis-based combination therapies as a promising approach for patients with 3q26 AML

• Genetic targeting strategies:

  • Genetic inhibition of PA2G4 has demonstrated efficacy in abrogating oncogenic signaling in AML models, including patient-derived xenografts

  • This provides proof-of-concept for RNA-based therapeutic approaches targeting PA2G4

How should researchers interpret multiple bands in PA2G4 Western blots?

When conducting Western blot analysis of PA2G4, researchers frequently encounter multiple bands. Here's how to interpret them:

Expected band patterns:

• 38-42 kDa band: Corresponds to the PA2G4-p42 isoform

• 48 kDa band: Corresponds to the PA2G4-p48 isoform

Tissue-specific expression patterns:

• In hepatocellular carcinoma, PA2G4-p48 is typically the predominant isoform, with PA2G4-p42 often nearly undetectable

• Expression patterns may vary in other tissue types

Validation strategies:

• Use positive control lysates (PC-3, HEK-293, Jurkat cells) with known PA2G4 expression patterns

• Confirm specificity using genetic knockdown/knockout controls

• If necessary, use isoform-specific antibodies to differentiate between variants

What factors influence PA2G4 antibody sensitivity in different applications?

Several factors can impact PA2G4 antibody performance:

Epitope-specific considerations:
Different antibodies target distinct regions of PA2G4, including:

• AA 1-394 (full-length)

• AA 322-350 (C-terminal)

• AA 228-255 (internal region)

• AA 1-110 (N-terminal)

These epitope differences affect antibody performance across applications and species.

Application-specific dilution requirements:

Cell/tissue type influences:
Antibody performance varies across cellular contexts. Validated positive controls include:

• WB: PC-3, HEK-293, Jurkat, HeLa cells

• IHC: Human breast cancer tissue

• IF: HeLa cells

• IP: Jurkat cells

How can PA2G4 antibodies be utilized in studying protein-protein interactions?

PA2G4 functions through various protein-protein interactions that can be studied using specialized approaches:

Co-immunoprecipitation strategies:

• Use 0.5-4.0 μg of PA2G4 antibody per 1.0-3.0 mg of total protein lysate

• Validated in Jurkat cells for studying endogenous interactions

• Consider cross-linking antibodies to beads to prevent antibody co-elution

Surface Plasmon Resonance (SPR) approaches:

• Successful protocol includes:

  • Buffer exchange of recombinant PA2G4 into PBS via overnight dialysis at 4°C

  • Protein concentration to 0.5 mg/mL

  • Biotinylation using EZ-Link Sulfo-NHS-LC-Biotin (20:1 molar excess)

  • Isolation of biotinylated protein using Superdex 200 10/300 SEC column

  • SPR experiments performed at 25°C in HEPES Buffered Saline

In silico interaction modeling:

• Fast-Rigid Exhaustive Docking (FRED) has been successfully used to model PA2G4 interactions

• Docking receptors can be created using PA2G4 structure (PDB: 2Q8K)

• This approach is particularly valuable for developing small molecule inhibitors targeting PA2G4 interactions

How is PA2G4 implicated in drug resistance mechanisms?

Recent research highlights PA2G4's role in therapeutic resistance:

In acute myeloid leukemia (AML), PA2G4 contributes to resistance against histone deacetylase inhibitors (HDACis). Studies demonstrate that PA2G4 overexpression rescues AML cells from the inhibitory effects of HDACis, while genetic and small molecule inhibition of PA2G4 enhances sensitivity to these compounds .

This positions PA2G4 as a critical component of drug resistance pathways, suggesting that PA2G4 inhibition could be a valuable strategy to overcome resistance in 3q26 AML and potentially other cancers where PA2G4 is overexpressed.

What techniques are emerging for spatial analysis of PA2G4 in the tumor microenvironment?

Advanced immunohistochemical and immunofluorescence approaches are being employed to analyze PA2G4's role in the tumor microenvironment:

Subcellular localization analysis:

• PA2G4 protein expression has been observed in the cytoplasm of malignant tumor cells

• In normal tissue, PA2G4 is detected in full thickness nasopharyngeal mucosa epithelium, including cilia

Multi-marker immunohistochemistry approaches:

• PA2G4 immunohistochemistry can be combined with other markers to characterize its expression in relation to other key proteins in the tumor microenvironment

• This approach has proven valuable in cancers like nasopharyngeal carcinoma and hepatocellular carcinoma

Continued refinement of these techniques will enhance our understanding of PA2G4's spatial context within tumors and potentially identify new therapeutic strategies.